Ajovy (fremanezumab-vfrm) / Teva 
Welcome,         Profile    Billing    Logout  
 7 Diseases   13 Trials   13 Trials   1459 News 


«12345678910111213...1617»
  • ||||||||||  Ajovy (fremanezumab) / Otsuka, Teva
    Trial completion date, Trial primary completion date:  A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents (clinicaltrials.gov) -  May 17, 2022   
    P3,  N=550, Recruiting, 
    In this real-world study, fremanezumab demonstrated effectiveness for migraine regardless of migraine type or the presence of factors contributing to DTT migraine (MO, GAD, MDD, or prior exposure to a different CGRP mAb). Trial completion date: Nov 2027 --> Apr 2027 | Trial primary completion date: Jul 2027 --> Dec 2026
  • ||||||||||  Ajovy (fremanezumab) / Otsuka, Teva
    Retrospective data, Journal, Real-world evidence:  A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States. (Pubmed Central) -  May 12, 2022   
    Overall, adherence and persistence to fremanezumab in this real-world study was high in patients with migraine, with higher rates observed for quarterly fremanezumab. Patients who were persistent for ≥ 6 months experienced significant reductions in acute and preventive migraine medication use, while a subgroup of migraine patients with comorbid depression and anxiety at baseline showed significant reductions in antidepressant and anxiolytic medication use.
  • ||||||||||  Ajovy (fremanezumab) / Otsuka, Teva
    Trial completion date, Trial primary completion date:  A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents (clinicaltrials.gov) -  May 11, 2022   
    P3,  N=550, Recruiting, 
    Patients who were persistent for ≥ 6 months experienced significant reductions in acute and preventive migraine medication use, while a subgroup of migraine patients with comorbid depression and anxiety at baseline showed significant reductions in antidepressant and anxiolytic medication use. Trial completion date: Dec 2024 --> Nov 2027 | Trial primary completion date: Aug 2024 --> Jul 2027
  • ||||||||||  Ajovy (fremanezumab) / Otsuka, Teva
    Trial completion date, Trial primary completion date:  A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Patients 6 to 17 Years of Age (clinicaltrials.gov) -  May 11, 2022   
    P3,  N=418, Recruiting, 
    Trial completion date: Dec 2024 --> Nov 2027 | Trial primary completion date: Aug 2024 --> Jul 2027 Trial completion date: Dec 2023 --> Mar 2026 | Trial primary completion date: Dec 2023 --> Mar 2026
  • ||||||||||  Ajovy (fremanezumab) / Otsuka, Teva
    Trial completion date, Trial primary completion date:  Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden (clinicaltrials.gov) -  Apr 13, 2022   
    P4,  N=40, Completed, 
    This real-world study demonstrated effectiveness of fremanezumab treatment for up to 6 months, irrespective of dosing regimen or number of prior migraine preventive treatment failures, reflecting ongoing, clinically meaningful improvements in patient outcomes. Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion date, Trial primary completion date:  CGRP-1: CGRP Inhibition, Autonomic Function, and Migraine (clinicaltrials.gov) -  Apr 11, 2022   
    P=N/A,  N=120, Recruiting, 
    Younger age emerges as a potential response predictor. Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Feb 2022 --> Feb 2024
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
    Late response to anti-CGRP (calcitonin gene-related peptide) monoclonal antibodies: implication for clinical practice (Room Istanbul) -  Apr 9, 2022 - Abstract #EAN2022EAN_264;    
    Late response to antiCGRP mAbs may occur in more than one third of migraine patients considered not responders at 12 weeks. Our findings suggest extending the efficacy treatment evaluation for antiCGRP mAbs to 6 months, also in terms of reimbursement policies.
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
    Clinical, Journal:  Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. (Pubmed Central) -  Apr 8, 2022   
    Our findings suggest extending the efficacy treatment evaluation for antiCGRP mAbs to 6 months, also in terms of reimbursement policies. The cessation of CGRP(-receptor) antibodies migraine prophylaxis was associated with a significant increase of migraine frequency and acute medication intake over time.
  • ||||||||||  Ajovy (fremanezumab) / Otsuka, Teva
    Enrollment open:  Fremanezumab, Migraine and Sleep (clinicaltrials.gov) -  Mar 31, 2022   
    P4,  N=100, Recruiting, 
    However, because there are several limitations, the findings of the current NMA should be taken into consideration with caution. Not yet recruiting --> Recruiting
  • ||||||||||  Ajovy (fremanezumab) / Otsuka, Teva
    Real-World Reductions in Acute Medication Use for Patients with Migraine Initiating Fremanezumab: A 12-Month Retrospective US Claims Analysis (In-person & Virtual) -  Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1365;    
    Significant reductions were also seen in mean (SD) annual numbers of total claims for migraine-related acute medication prescriptions (10.6 [10.7] to 9.3 [10.5]), triptans (4.9 [6.4] to 4.0 [5.7]), NSAIDs (2.0 [3.3] to 1.9 [3.4]), and opioids (2.6 [5.9] to 2.5 [5.7]; all P <0.05), except for ergots (0.1 [0.7] to 0.1 [0.9]; P =0.3713). CONCLUSION Fremanezumab treatment was associated with statistically significant reductions in acute medication use from 12 months pre-index to 12 months post-index.
  • ||||||||||  Ajovy (fremanezumab) / Otsuka, Teva
    Fremanezumab for Preventive Treatment in Migraine: The FINESSE Study (Poster Hall) -  Mar 6, 2022 - Abstract #AAN2022AAN_3448;    
    More than a third of all patients reported improved MIDAS and HIT-6 scores. The study is still recruiting and a later interim analysis will reveal further information.